Novo Nordisk has decided that it wants its own triple agonist, and is willing to hand over $200 million upfront to United Laboratories’ subsidiary United Biotechnology. In return for the global ...

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer seeks a ...

Novo Nordisk and The United Laboratories (TUL) have entered into an exclusive license agreement for UBT251, a triple receptor agonist targeting GLP-1, GIP, and glucagon, currently in early-stage ...

Novo Nordisk has said will be gaining exclusive worldwide rights to United Laboratories International’s investigational triple receptor agonist in a deal worth up to $2bn. The candidate, UBT251, is a ...

Novo Nordisk is expanding its prospects in ... William Blair analysts noted that the pharma giant discontinued development of a triple agonist for chronic weight management in 2020 due to the ...

Danish biopharma powerhouse Novo Nordisk is taking another bold move ... Novo picked up the new triple agonist, UBT251, from China-based United Biotechnology. The candidate, which is still in ...

Novo Nordisk has moved to shore up its obesity ... The drug candidate is a triple agonist – targeting GLP-1, GIP, and glucagon – and is currently in early-stage clinical development for ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO ... Researchers believe the GLP-1 agonist market could triple over the next decade to over $150 billion. Where to invest $1,000 right now?